Compare STRT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | CCCC |
|---|---|---|
| Founded | 1908 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.3M | 404.7M |
| IPO Year | 1996 | 2020 |
| Metric | STRT | CCCC |
|---|---|---|
| Price | $78.36 | $4.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $93.00 | $12.20 |
| AVG Volume (30 Days) | 78.5K | ★ 3.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.53 | ★ 16.45 |
| EPS | ★ 4.04 | N/A |
| Revenue | ★ $439,195,000.00 | $35,947,000.00 |
| Revenue This Year | $4.22 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $19.27 | ★ N/A |
| Revenue Growth | ★ 5.24 | 1.02 |
| 52 Week Low | $57.01 | $1.44 |
| 52 Week High | $92.50 | $5.17 |
| Indicator | STRT | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 57.67 |
| Support Level | $77.01 | $2.10 |
| Resistance Level | $84.20 | $4.60 |
| Average True Range (ATR) | 3.42 | 0.38 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 9.83 | 44.41 |
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.